{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hellstrom A"],"funding":["NEI NIH HHS","NICHD NIH HHS","Department of Health"],"pagination":["576-86"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5069563"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["105(6)"],"pubmed_abstract":["<h4>Unlabelled</h4>Poor postnatal growth after preterm birth does not match the normal rapid growth in utero and is associated with preterm morbidities. Insulin-like growth factor 1 (IGF-1) axis is the major hormonal mediator of growth in utero, and levels of IGF-1 are often very low after preterm birth. We reviewed the role of IGF-1 in foetal development and the corresponding preterm perinatal period to highlight the potential clinical importance of IGF-1 deficiency in preterm morbidities.<h4>Conclusion</h4>There is a rationale for clinical trials to evaluate the potential benefits of IGF-1 replacement in very preterm infants."],"journal":["Acta paediatrica (Oslo, Norway : 1992)"],"pubmed_title":["Insulin-like growth factor 1 has multisystem effects on foetal and preterm infant development."],"pmcid":["PMC5069563"],"funding_grant_id":["NF-SI-0513-10012","R01 EY017017","NF-SI-0508-10274","U54 HD090255"],"pubmed_authors":["Beardsall K","Hellstrom A","Dunger D","van Marter L","Hallberg B","van Weissenbruch M","Ley D","Hansen-Pupp I","Hard AL","Ramenghi LA","Lofqvist C","Smith LE"],"additional_accession":[]},"is_claimable":false,"name":"Insulin-like growth factor 1 has multisystem effects on foetal and preterm infant development.","description":"<h4>Unlabelled</h4>Poor postnatal growth after preterm birth does not match the normal rapid growth in utero and is associated with preterm morbidities. Insulin-like growth factor 1 (IGF-1) axis is the major hormonal mediator of growth in utero, and levels of IGF-1 are often very low after preterm birth. We reviewed the role of IGF-1 in foetal development and the corresponding preterm perinatal period to highlight the potential clinical importance of IGF-1 deficiency in preterm morbidities.<h4>Conclusion</h4>There is a rationale for clinical trials to evaluate the potential benefits of IGF-1 replacement in very preterm infants.","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Jun","modification":"2021-02-21T12:05:00Z","creation":"2019-03-27T02:27:03Z"},"accession":"S-EPMC5069563","cross_references":{"pubmed":["26833743"],"doi":["10.1111/apa.13350"]}}